Contract development and manufacturing organization (CDMO) Sterling Pharma Solutions is investing £6m into its pilot plant facility at its UK site to enhance its scale-up and small to midscale commercial API manufacturing capabilities.
The expansion will increase the pilot plant’s capacity by 33% and enhance the site’s production capabilities and flexibility for small to mid-scale batch production.
The investment will add three new reactor trains at scales of 225L, 500L and 1,360L to the cGMP facility. This will help to meet growing market demand for API batch sizes in the 10-100kg range and will complement the CDMO’s API full service offering and current scale-up capabilities from grams to tons.
As part of the investment the 40-acre site in Dudley, North East England, will also add a range of new capabilities to expand the ability to handle potent compounds across a range of equipment scales.
“Over the last decade API manufacture has steadily started to move back to the west, as customers begin to look for partners who can offer reliability, high quality and the ability to handle increasingly complex products,” Kevin Cook, CEO at Sterling Pharma Solutions said. “This latest investment has been driven by demand for a full-service API development and manufacturing offering. More and more of our customers are interested in outsourcing the entire process and by adding more small-scale equipment to our facility we’ll be able to increase our capacity and cater for additional projects from proof of concept through to commercial manufacture.”
The expansion follows an investment in 2017 into the site’s milling, micronisation and solid form facility. Both investments form part of a strategic development plan totaling almost £12m. The facilities are expected to be operational by mid-2018.